v3.26.3
Investments, at Fair Value - Schedule of Refinancing Transaction (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2026
Dec. 31, 2025
Schedule of Refinancing Transaction [Line Items]    
Balance as of beginning $ 37,595 $ 34,808
Amounts receivable from the royalty agreement [1] (1,118) (1,640)
Principal payments (7,132) (9,875)
Proceeds from the sale of Subsequent Penny Warrants   (28,500)
Interest payments (764) (1,845)
Change in fair value (3,428) [2] 44,647
Balance as of ending 25,153 37,595
Tranche A [Member]    
Schedule of Refinancing Transaction [Line Items]    
Balance as of beginning 23,063 16,486
Amounts receivable from the royalty agreement [1]
Principal payments
Proceeds from the sale of Subsequent Penny Warrants   (28,500)
Interest payments
Change in fair value (4,347) [2] 35,077
Balance as of ending 18,716 23,063
Tranche B [Member]    
Schedule of Refinancing Transaction [Line Items]    
Balance as of beginning 14,532 18,322
Amounts receivable from the royalty agreement [1] (1,118) (1,640)
Principal payments (7,132) (9,875)
Proceeds from the sale of Subsequent Penny Warrants  
Interest payments (764) (1,845)
Change in fair value 919 [2] 9,570
Balance as of ending $ 6,437 $ 14,532
[1] As of September 30, 2026 and December 31, 2025, $773 and $449, respectively, were included under prepaid expenses and other current assets.
[2] During the nine months ended September 30, 2026, the Company received an extension fee of $1,000 from Scilex in consideration for the extension of the maturity of the Tranche A Note and the Tranche B Note. The extension fee is presented separately within “Financial income, net” (see Note 15) and is not included in the change in fair value above. See “Developments during the nine months ended September 30, 2026” above.